From GlobeNewswire: 2025-02-21 09:00:00

Biostax Corp announced the voluntary delisting of its common stock from the OTC Pink marketplace following strong shareholder support. The Company will file a Form 25 with the SEC on March 15, 2025, with the delisting expected to become effective ten days after. CEO Noreen Griffin stated the decision will better position Biostax for long-term growth while reducing costs. Biostax remains committed to advancing its pipeline, including FDA-authorized clinical trials for JKB-122 in autoimmune hepatitis and planned trials for NASH, NAFLD, and HIV treatment. The Company’s common stock will no longer be traded on the OTC Pink marketplace post-delisting.



Read more at GlobeNewswire: Biostax Corp Announces Voluntary Delisting from OTC Pink